Literature DB >> 28397847

Acute coronary syndromes: Similar bleeding risks with low-dose rivaroxaban versus aspirin.

Karina Huynh.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28397847     DOI： 10.1038/nrcardio.2017.42

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  1 in total

1.  Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.

Authors:  E Magnus Ohman; Matthew T Roe; P Gabriel Steg; Stefan K James; Thomas J Povsic; Jennifer White; Frank Rockhold; Alexei Plotnikov; Hardi Mundl; John Strony; Xiang Sun; Steen Husted; Michal Tendera; Gilles Montalescot; M Cecilia Bahit; Diego Ardissino; Héctor Bueno; Marc J Claeys; Jose C Nicolau; Jan H Cornel; Shinya Goto; Róbert Gábor Kiss; Ümit Güray; Duk-Woo Park; Christoph Bode; Robert C Welsh; C Michael Gibson
Journal:  Lancet       Date:  2017-03-18       Impact factor: 79.321
  1 in total
  1 in total

1.  Efficacy and safety of adding rivaroxaban to the anti-platelet regimen in patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Jun Yuan
Journal:  BMC Pharmacol Toxicol       Date:  2018-05-02       Impact factor: 2.483
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.